Clinical features and structured clinical evaluation of vasculitis

Best Pract Res Clin Rheumatol. 2018 Feb;32(1):31-51. doi: 10.1016/j.berh.2018.10.001. Epub 2018 Nov 22.

Abstract

Systemic vasculitides are a group of heterogeneous conditions with overlapping patterns of clinical and laboratory manifestations. Moreover, clinical features can be non-specific and seemingly disparate. A major factor in defining optimal therapy and measuring treatment response is careful disease assessment targeting four main domains: activity, damage, prognosis and quality of life/function. Assessment tools such as the Birmingham Activity Score and the Vasculitis Damage Index have become a core feature of clinical trials in ANCA-associated vasculitis (AAV) and formed the basis for sound clinical management of these complex conditions. We are still lacking accurate definitions of disease activity and damage progression in large-vessel vasculitis. There is an increasing interest in the role of patient-reported outcomes as a measure of disease impact; a disease-specific measure for use in AAV is being validated. We review how best to evaluate patients with large-, medium- and small-vessel vasculitis.

Keywords: ANCA-Associated vasculitis; Damage; Disease activity; Disease assessment; Giant cell arteritis; Patient-reported outcomes; Prognosis; Quality of life; Takayasu arteritis; Vasculitis.

Publication types

  • Review

MeSH terms

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis*
  • Disease Progression
  • Humans
  • Prognosis
  • Quality of Life / psychology*